A double-blind placebo-controlled randomized phase II trial assessing the activity and safety of regorafenib (REG) in patients (pts) with nonadipocytic soft tissue sarcoma (STS) previously treated with pazopanib (PAZ).

Nicolas Penel,Jean-Yves Blay,Jennifer Wallet,Isabelle Ray-Coquard,Axel Le Cesne,Thomas Ryckewaert,Antoine Italiano,Sébastien Salas,Corinne Delcambre,Emmanuelle Bompas,François Bertucci,Esma Saada-Bouzid,Loic Chaigneau,Christine Chevreau,Julien Théry,Emilie Decoupigny,Marie Vanseymortier,Marie-Cécile Le Deley,Olivier Mir

A double-blind placebo-controlled randomized phase II trial assessing the activity and safety of regorafenib (REG) in patients (pts) with nonadipocytic soft tissue sarcoma (STS) previously treated with pazopanib (PAZ).

2019

Nicolas Penel
Jean-Yves Blay
Jennifer Wallet
Isabelle Ray-Coquard
Axel Le Cesne
Thomas Ryckewaert
Antoine Italiano
Sébastien Salas
Corinne Delcambre
Emmanuelle Bompas
François Bertucci
Esma Saada-Bouzid
Loic Chaigneau
Christine Chevreau
Julien Théry
Emilie Decoupigny
Marie Vanseymortier
Marie-Cécile Le Deley
Olivier Mir

11021Background: After we demonstrated the activity of REG in pts with advanced non-adipocytic STS (MirTLO 2016), we conducted a dedicated study in pts previously treated with PAZ+chemo. Methods: W...

Keywords:

Internal medicine
Oncology
Regorafenib
Pazopanib
Pathology
Soft tissue sarcoma
Placebo
Medicine
previously treated
double blind
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations